Desmopressin acetate as an add-on therapy in patients with schizophreni?l

Desmopressin acetate as an add-on therapy in patients with schizophrenia; a double-blind, randomized, controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201208071556N45

Enrollment

Registered

2012-08-11

Start date

2012-09-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. schizophrenia

Interventions

Intervention 1: Tablets Risperidone (6 mg/day) combined with 20microgram/day Desmopressin Acetate as intervention group for 8 weeks. Intervention 2: Tablet Risperidone (6 mg/day) combined with placeb

Treatment - Drugs

Placebo

Tablets Risperidone (6 mg/day) combined with 20microgram/day Desmopressin Acetate as intervention group for 8 weeks

Tablet Risperidone (6 mg/day) combined with placebo as control group for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:1- Age between 18-50; 2-Diagnosis of Schizophrenia based on DSM- IV; 3- chronic Schizophrenia( duration of the disorder>2 years); 4- Minimum Score of 60 on Positive and Negative Scale; 5-receiving a constant dose of risperidone during the last month Exclusion Criteria:1- Substance dependence during the last 6 months;2- IQ <70; 3-any other mental disorder on axis I; 4-Any serious medical or neurological problem ;5-receiving ECT during the last 14 days, 6- hepatic disease; 7-nursing or pregnant women

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactProf. Shahin Akhondzadeh

Tehran University of Medical Sciences

s.akhond@sina.tums.ac.ir+98 21 5541 2222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026